Skip to main content
PIQRAY header image

PIQRAY is a once-daily medication given in combination with fulvestrant1

PIQRAY + fulvestrant starting dose

Continue treatment until disease progression or until unacceptable toxicity occurs1

*Tablets should not be chewed, crushed, or split prior to swallowing. No tablet should be ingested if it is broken, cracked, or otherwise not intact.

Blister pack is designed to help patients stay on track with treatment1

PIQRAY approved doses:

PIQRAY approved doses: 300 mg, 250 mg, 200 mg


Dose modifications for PIQRAY 


Certain ARs may require dose modifications1
PIQRAY dose modifications
PIQRAY patient brochure

PIQRAY Patient Brochure

The PIQRAY Patient Brochure is designed to help your patient start their treatment journey. They will learn about why they are prescribed PIQRAY, dosing and administration, and serious and common ARs associated with treatment.

Patient management resources
PIQRAY patient management brochure


Managing Patients on PIQRAY
Take an in-depth look at managing selected ARs. 

PIQRAY Monitoring AR Checklist

Monitoring AR Checklist
Monitor for ARs before and during treatment.

Important Safety Information

PIQRAY is contraindicated in patients with severe hypersensitivity to it or any of its components.

Severe Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can occur in patients treated with PIQRAY. Severe hypersensitivity reactions were manifested by symptoms, including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia...


PIQRAY® (alpelisib) tablets is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen...

Reference: 1. PIQRAY [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.